IO Biotech Inc

NASDAQ IOBT

Data sourced from

and

Daily

Download Data

IO Biotech Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

IO Biotech Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

IO Biotech Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
IO Biotech Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
IO Biotech Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: IOBT

IO Biotech Inc

CEO	Dr. Mai-Britt Zocca Ph.D.
IPO Date	Nov. 5, 2021
Location	Denmark
Headquarters	Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key trends